Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine

Bryant K. A.; Frenck R.; Gurtman A.; Rubino J.; Treanor J.; Thompson A.; Jones T. R.; Sundaraiyer V.; Baxter L. M.; Gruber W. C.; Emini E. A.; Scott D. A.; Schmoele-Thoma B.

首页> 外文期刊>Vaccine >Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine

【24h】

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine

机译：初次接种23价肺炎球菌多糖疫苗的18-49岁成人13价肺炎球菌结合疫苗的免疫原性和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Based on the success of vaccination with pneumococcal conjugate vaccines (PCVs) in children, recent studies have focused on PCVs in adults. Data from a randomized, double-blind study comparing the immunogenicity, tolerability, and safety of the 13-valent PCV (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in PPSV23-naive adults 60-64 years of age have been published. The same study also included a cohort of adults aged 18-49 years that received open-label PCV13. The purpose of this cohort was to examine the immunogenicity, safety, and tolerability of PCV13 in adult subjects 18-49 years of age compared with adults 60-64 years of age for whom PCV13 is approved.

机译：背景：基于在儿童中成功接种肺炎球菌结合疫苗（PCV）的经验，最近的研究集中于成人的PCV。来自一项随机双盲研究的数据，该数据比较了在60-64岁的未出生PPSV23的成年人中13价PCV（PCV13）和23价肺炎球菌多糖疫苗（PPSV23）的免疫原性，耐受性和安全性发表。这项研究还包括接受开放标签PCV13的18-49岁成年人群。该队列的目的是检查与批准PCV13的60-64岁成年人相比，PCV13在18-49岁的成年人受试者中的免疫原性，安全性和耐受性。

著录项

来源
《Vaccine》 |2015年第43期|共7页
作者
Bryant K. A.; Frenck R.; Gurtman A.; Rubino J.; Treanor J.; Thompson A.; Jones T. R.; Sundaraiyer V.; Baxter L. M.; Gruber W. C.; Emini E. A.; Scott D. A.; Schmoele-Thoma B.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Pneumococcal disease; Streptococcus pneumoniae; 13-Valent pneumococcal conjugate vaccine (PCV13); Adults;

机译：肺炎球菌病;肺炎链球菌;13价肺炎球菌结合疫苗（PCV13）;成人;

相似文献

外文文献
中文文献
专利

1. Response to Letter to the Editor regarding: Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine [J] . Bryant Kristina, Frenck Robert W. Jr. Vaccine . 2016,第38期

机译：致致编辑的信的回复：初次使用23价肺炎球菌多糖疫苗的18-49岁成人的13价肺炎球菌结合疫苗的免疫原性和安全性
2. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults >= 65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine [J] . Peterson James T., Stacey Helen L., MacNair John E., Human vaccines & immunotherapeutics. . 2019,第3期

机译：15价肺炎球菌缀合物疫苗的安全性和免疫原性与成人中的13价肺炎球菌缀合物疫苗> = 65岁以前用23价肺炎球菌多糖疫苗接种疫苗
3. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults [J] . Jackson Lisa A., Gurtman Alejandra, van Cleeff Martin, Vaccine . 2013,第35期

机译：在未接种肺炎球菌疫苗的成年人中，与23价肺炎球菌多糖疫苗相比，13价肺炎球菌结合疫苗的免疫原性和安全性
4. Evaluation of the effectiveness of a 13-valent pneumococcal conjugated vaccine implemented in the municipality of Campos de Goytacazes, Brazil [C] . Kury C.M.H., Vitral C.L, Kury M.M.H., World Congress of the World Society for Pediatric Infectious Diseases . 2014

机译：评估在巴西坎波德·戈科塔斯市政府实施的13价肺炎球菌共轭疫苗的有效性
5. Immune responses of pneumococcal polysaccharide and conjugate vaccines in adults: Effect of human immunodeficiency virus infection [D] . Ahmed, Faruque 1995

机译：成人肺炎球菌多糖和结合疫苗的免疫应答：人类免疫缺陷病毒感染的影响
6. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine [O] . James T. Peterson, Helen L. Stacey, John E. MacNair, 2019

机译：15价肺炎球菌结合疫苗与13价肺炎球菌结合疫苗相比在先前接种过23价肺炎球菌多糖疫苗的65岁以上成年人中的安全性和免疫原性
7. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults [O] . Jackson Lisa A., Gurtman Alejandra, van Cleeff Martin, 2013

机译：13价肺炎球菌结合疫苗与23价肺炎球菌多糖疫苗相比在未接种肺炎球菌的成年人中的免疫原性和安全性

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine

摘要

著录项

相似文献

相关主题

期刊订阅